Department of Pharmaceutics, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, India.
Biomed Res Int. 2013;2013:909045. doi: 10.1155/2013/909045. Epub 2013 Jul 18.
The objective of the present study was to develop self micro emulsifying formulation (SMEF) of valsartan to improve its oral bioavailability. The formulations were screened on the basis of solubility, stability, emulsification efficiency, particle size and zeta potential. The optimized liquid SMEF contains valsartan (20% w/w), Capmul MCM C8 (16% w/w), Tween 80 (42.66% w/w) and PEG 400 (21.33% w/w) as drug, oil, surfactant and co-surfactant, respectively. Further, Liquid SMEF was adsorbed on Aerosol 200 by spray and freeze drying methods in the ratio of 2 : 1 and transformed into free flowing powder. Both the optimized liquid and solid SMEF had the particle size <200 nm with rapid reconstitution properties. Both drying methods are equally capable for producing stable solid SMEF and immediate release of drug in in vitro and in vivo conditions. However, the solid SMEF produced by spray drying method showed high flowability and compressibility. The solid state characterization employing the FTIR, DSC and XRD studies indicated insignificant interaction of drug with lipid and adsorbed excipient. The relative bioavailability of solid SMEF was approximately 1.5 to 3.0 folds higher than marketed formulation and pure drug. Thus, the developed solid SMEF illustrates an alternative delivery of valsartan as compared to existing formulations with improved bioavailability.
本研究旨在开发缬沙坦自微乳制剂 (SMEF) 以提高其口服生物利用度。根据溶解度、稳定性、乳化效率、粒径和zeta 电位对制剂进行筛选。优化的液体 SMEF 含有缬沙坦(20%w/w)、Capmul MCM C8(16%w/w)、吐温 80(42.66%w/w)和 PEG 400(21.33%w/w),分别作为药物、油相、表面活性剂和助表面活性剂。进一步,将液体 SMEF 以 2:1 的比例通过喷雾和冷冻干燥吸附到 Aerosol 200 上,并转化为自由流动的粉末。优化后的液体和固体 SMEF 的粒径均<200nm,具有快速再构成特性。两种干燥方法都能够生产出稳定的固体 SMEF,并在体外和体内条件下实现药物的即刻释放。然而,喷雾干燥法制备的固体 SMEF 表现出高流动性和可压缩性。采用傅里叶变换红外光谱 (FTIR)、差示扫描量热法 (DSC) 和 X 射线衍射 (XRD) 研究的固态特性表明,药物与脂质和吸附赋形剂之间没有明显的相互作用。与市售制剂和纯药物相比,固体 SMEF 的相对生物利用度约提高 1.5 至 3.0 倍。因此,与现有制剂相比,开发的固体 SMEF 说明了缬沙坦的替代给药方式,具有改善的生物利用度。